Symbicort Indications/Uses

Turbuhaler 80/4.5 mcg/dose & Rapihaler: Asthma: Symbicort is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.
Turbuhaler & Rapihaler 80/4.5 mcg/dose: Note: Symbicort (80/4.5 micrograms/inhalation) is not appropriate in patients with severe asthma.
Turbuhaler 160/4.5 mcg/dose: Asthma: Symbicort is indicated in adults and adolescents (aged 12 years and older) for the treatment of asthma to relieve symptoms and the reduction of the risk of exacerbations, where the use of inhaled corticosteroids is appropriate.
Chronic Obstructive Pulmonary Disease (COPD): Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Rapihaler 160/4.5 mcg/dose Chronic Obstructive Pulmonary Disease (COPD): Symbicort Rapihaler is indicated for the symptomatic treatment of patients with severe COPD (FEV1 ≤ 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.